Regent Pacific Group (HKSE:00575) ROCE % : 0.00% (As of Jun. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Regent Pacific Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Regent Pacific Group's annualized ROCE % for the quarter that ended in Jun. 2024 was 0.00%.

Regent Pacific Group ROCE % Historical Data

The historical data trend for Regent Pacific Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regent Pacific Group ROCE % Chart

Regent Pacific Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-58.59

-32.59

-22.73

-117.83

-845.03

Regent Pacific Group Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															-107.99	-166.58	-275.55	-465.36	-

Regent Pacific Group ROCE % Calculation

Regent Pacific Group's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-237.285	/	( ( (204.896 - 142.597)	+	(21.828 - 27.967) )	/ 2 )
	=	-237.285	/	( (62.299	+	-6.139)	/ 2 )
	=	-237.285	/	28.08
	=	-845.03 %

Regent Pacific Group's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-39.94	/	( ( (21.828 - 27.967)	+	(6.162 - 28.21) )	/ 2 )
	=	-39.94	/	( ( -6.139	+	-22.048 )	/ 2 )
	=	-39.94	/	-14.0935
	=	0 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Regent Pacific Group (HKSE:00575) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Regent Pacific Group ROCE % Related Terms

Thank you for viewing the detailed overview of Regent Pacific Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Regent Pacific Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regent Pacific Group Ltd (HKSE:00575) » Definitions » ROCE %

Traded in Other Exchanges

RPGLF:USA

Address

5 Queen's Road Central, 8th Floor, Henley Building, Hong Kong, HKG

Website

https://www.endurancerp.com

Regent Pacific Group Ltd is an investment holding company that runs through two segments: Biopharma and Corporate Investment. Its Biopharma segment is engaged in the research, development, manufacturing, marketing, and sales of pharmaceutical products, and it also develops artificial intelligence (AI) systems for the field of biological aging clocks. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The majority of its revenue comes from the Biopharma segment. Its geographical segments are China, Europe, Hong Kong, and Taiwan.

Executives

Mellon James
Galloway Limited
2464344 Ontario Inc.	2101 Beneficial owner
Caravel Ds Fund Ltd.	2101 Beneficial owner

Regent Pacific Group Headlines

No Headlines